Drug Profile
Teriparatide biosimilar - Stelis Biopharma
Alternative Names: SBL 001; Stelis Teriparatide [rh-PTH (1-34)]Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Stelis Biopharma
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for phase-I development in Osteoporosis(In volunteers) in Australia (SC, Injection)
- 15 Jun 2018 Stelis Biopharma completes a phase I trial in healthy volunteers in Australia (ACTRN12618000013268p)
- 13 Mar 2018 Stelis Biopharma initiates enrolment in a phase I trial in volunteers in Australia (ACTRN12618000013268p)